Literature DB >> 25397458

Overall and cause-specific mortality in HIV-positive subjects compared to the general population.

Belen Alejos1, Victoria Hernando1, Jose López-Aldeguer2, Ferrán Segura3, José Antonio Oteo4, Rafael Rubio5, Arantza Sanvisens6, Paz Sobrino1, Julia Del Amo1, Cohort Coris7.   

Abstract

INTRODUCTION: Emerging non-AIDS related causes of death have been observed in HIV-positive subjects in industrialized countries. We aimed to analyze overall and cause-specific excess of mortality of HIV-positive patients compared to the general population and to assess the effect of prognostic factors.
MATERIAL AND METHODS: We used generalized linear models with Poisson error structure to estimate overall and cause-specific excess of mortality in HIV-positive patients from 2004 to 2012 in the cohort of the Spanish Network of HIV Research (CoRIS), compared to Spanish general population and to assess the impact of multiple risk factors. We investigated differences between short-term and long-term risk factors effects on excess of mortality. Multiple Imputation by Chained Equations was used to deal with missing data.
RESULTS: In 9162 patients there were 363 deaths, 16.0% were non-AIDS malignancies, 10.5% liver and 0.3% cardiovascular related. Excess mortality was 1.20 deaths per 100 person years (py) for all-cause mortality, 0.16 for liver, 0.10 for non-AIDS malignancies and 0.03 for cardiovascular. Short-term (first-year follow-up) excess Hazard Ratio (eHR) for global mortality for baseline AIDS was 4.27 (95% CI 3.06-6.01) and 1.47 (95% CI 0.95-2.27) for HCV coinfection; long-term (subsequent follow-up) eHR for baseline AIDS was 0.88 (95% CI 0.58-1.35) and 4.48 (95% CI 2.71-7.42) for HCV coinfection. Lower CD4 count and higher viral load at entry, lower education, being male and over 50 years were predictors for overall excess mortality. Excess of liver mortality was higher in patients with CD4 counts at entry below 200 cells compared to those above 350 (eHR: 6.49, 95% CI 1.21-34.84) and in HCV-coinfected patients (eHR: 3.85, 95% CI 0.85- 17.37), although it was borderline significant. Patients over 50 years old (eHR: 5.55, 95%CI 2.4-12.85) and HCV coinfected (eHR: 5.81, 95% CI 2.6-13) showed a higher risk of non-AIDS malignancies mortality excess. Excess of cardiovascular mortality was related with HCV coinfection (eHR: 6.68, 95% CI 1.25-35.73).
CONCLUSIONS: Our results show overall, liver, non-AIDS malignancies and cardiovascular excess of mortality associated with being HIV-positive, despite improvements in HIV disease management and antiretroviral therapies. Differential short-term and long-term effect of AIDS before entry and HCV coinfection was found for overall mortality.

Entities:  

Year:  2014        PMID: 25397458      PMCID: PMC4225377          DOI: 10.7448/IAS.17.4.19711

Source DB:  PubMed          Journal:  J Int AIDS Soc        ISSN: 1758-2652            Impact factor:   5.396


  13 in total

Review 1.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

Review 2.  HIV and the Gut Microbiota: Composition, Consequences, and Avenues for Amelioration.

Authors:  Ivan Vujkovic-Cvijin; Ma Somsouk
Journal:  Curr HIV/AIDS Rep       Date:  2019-06       Impact factor: 5.071

3.  The Risk of Cardiovascular Disease, Diabetes, Liver-Related Outcomes, and Death Over 10 Years in HIV/HCV-Coinfected Patients With and Without Steatosis.

Authors:  Carrie Down; Natasha Mehta; Kristen Marks
Journal:  AIDS Res Hum Retroviruses       Date:  2016-06-21       Impact factor: 2.205

Review 4.  Aging in HIV-Infected Subjects: A New Scenario and a New View.

Authors:  Eugenia Negredo; David Back; José-Ramón Blanco; Julià Blanco; Kristine M Erlandson; Maite Garolera; Giovanni Guaraldi; Patrick Mallon; José Moltó; José Antonio Serra; Bonaventura Clotet
Journal:  Biomed Res Int       Date:  2017-12-21       Impact factor: 3.411

5.  Immediate Antiretroviral Therapy Decreases Mortality Among Patients With High CD4 Counts in China: A Nationwide, Retrospective Cohort Study.

Authors:  Yan Zhao; Zunyou Wu; Jennifer M McGoogan; Cynthia X Shi; Aihua Li; Zhihui Dou; Ye Ma; Qianqian Qin; Ron Brookmeyer; Roger Detels; Julio S G Montaner
Journal:  Clin Infect Dis       Date:  2018-02-10       Impact factor: 9.079

6.  Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis.

Authors:  Raphael Mohr; Christoph Boesecke; Leona Dold; Robert Schierwagen; Carolynne Schwarze-Zander; Jan-Christian Wasmuth; Insa Weisensee; Jürgen Kurt Rockstroh; Jonel Trebicka
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

Review 7.  Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?

Authors:  Athanasios-Dimitrios Bakasis; Theodoros Androutsakos
Journal:  Cells       Date:  2021-05-15       Impact factor: 6.600

Review 8.  Lights and Shadows of Microbiota Modulation and Cardiovascular Risk in HIV Patients.

Authors:  Pablo Villoslada-Blanco; Patricia Pérez-Matute; José A Oteo
Journal:  Int J Environ Res Public Health       Date:  2021-06-25       Impact factor: 3.390

9.  Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role?

Authors:  Raphael Mohr; Robert Schierwagen; Carolynne Schwarze-Zander; Christoph Boesecke; Jan-Christian Wasmuth; Jonel Trebicka; Jürgen Kurt Rockstroh
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

10.  CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).

Authors:  Adam Trickey; Margaret T May; Philipp Schommers; Jan Tate; Suzanne M Ingle; Jodie L Guest; M John Gill; Robert Zangerle; Mike Saag; Peter Reiss; Antonella d'Arminio Monforte; Margaret Johnson; Viviane D Lima; Tim R Sterling; Matthias Cavassini; Linda Wittkop; Dominique Costagliola; Jonathan A C Sterne
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.